Clinical trials: completed, sponsored by Bayer
Hepatic Insufficiency, Liver Diseases
A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose
This is a research study to understand how liver impairment affects the way the body processes a new cancer medicine called sevabertinib (BAY 2927088).
- Conditions
- Hepatic Insufficiency, Liver Diseases, Pharmacokinetics, Drug Metabolism
- Trial name
- NCT07102095
- Testing
- Sevabertinib
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bayer
Solid Tumors Harboring NTRK Fusion
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of…
- Trial name
- NCT02122913
- Testing
- Larotrectinib (Vitrakvi, BAY2757556)
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Bayer
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
This is an observational study in which data from people in China with chronic heart failure with reduced ejection fraction (HFrEF) who will be receiving vericiguat treatment are collected.
- Trial name
- VERI-China (NCT05728502)
- Testing
- Vericiguat (Verquvo, BAY1021189), Standard of Care (SoC)
- Where
- China
- Volunteers
- 2,400 people
- Sponsor
- Bayer
Vasomotor Symptoms
A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elinzanetant in Healthy Female Participants
The aim of this study is to examine the relative bioavailability of elinzanetant when administered in new oral formulations (treatment B and C) after both single and multiple oral doses, compared to its administration in soft gel…
- Trial name
- NCT07229404
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bayer
Sepsis, Disseminated Intravascular Coagulation
An Observational Study to Learn About the Occurrence of Disseminated Intravascular Coagulation Among Adults With Sepsis in Japan
This is an observational study in which data already collected from people with sepsis (blood poisoning) and/or disseminated intravascular coagulation (DIC) are studied.
- Trial name
- NCT06373159
- Testing
- No study intervention
- Where
- Japan
- Volunteers
- 5,740 people
- Sponsor
- Bayer
Metastatic Hormone-sensitive Prostate Cancer
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive…
- Trial name
- ARASENS (NCT02799602)
- Testing
- BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel
- Where
- 322 sites in United States, Australia and 21 more
- Volunteers
- 1,306 people
- Sponsor
- Bayer
Vasomotor Symptoms Associated With Menopause, Hot Flashes
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause
Researchers are looking for a better way to treat women who have hot flashes after they have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the…
- Trial name
- OASIS-3 (NCT05030584)
- Testing
- Elinzanetant (BAY3427080)
- Where
- 86 sites in United States, Belgium and 7 more
- Volunteers
- 628 people
- Sponsor
- Bayer
Sleep Disturbances Associated With Menopause
An Observational Study to Learn More About How Menopause Affects Women's Sleep and How They Are Being Treated for Sleep Problems
This is an observational study in which data from women with sleep disturbances and vasomotor symptoms, also known as hot flashes, associated with menopause (SDM) are collected and studied.
- Trial name
- ESTeeM (NCT06728332)
- Testing
- No study intervention
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Bayer
Metastatic Colorectal Cancer (mCRC)
An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions
This is an observational study using data that has been collected from participants who received their usual treatments. Metastatic colorectal cancer (mCRC) is a cancer of the colon (large bowel) or the rectum (lowest part of the…
- Trial name
- STAR-T (NCT05839951)
- Testing
- Regorafenib (BAY73-4506, Stivarga®), TAS-102 (trifluridine and tipiracil, Lonsurf®), Bevacizumab
- Where
- United States
- Volunteers
- 818 people
- Sponsor
- Bayer
Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had: an acute stroke due to a blood clot that formed outside the…
- Conditions
- Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, High-risk Transient Ischemic Attack
- Trial name
- OCEANIC-STROKE (NCT05686070)
- Testing
- Asundexian (BAY2433334)
- Where
- 741 sites in United States, Argentina and 35 more
- Volunteers
- 12,327 people
- Sponsor
- Bayer
Hemophilia A, Prophylaxis of Bleeding
Prophylaxis Regimen for Hemophilia A Patients
Researchers are looking for a better way to treat people who have hemophilia A. Hemophilia A is a genetic bleeding disorder that is caused by the lack of a protein in the blood called "clotting factor 8" (FVIII).
- Trial name
- PREDICT (NCT05036278)
- Testing
- Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).
- Where
- 12 sites in United States
- Volunteers
- 21 people
- Sponsor
- Bayer
Sleep Disturbances Associated With Menopause
A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause
Researchers are looking for a better way to treat women who have sleep disturbances associated with menopause. Menopause is part of a natural aging process and happens when women's menstrual cycles, also called periods, stop.
- Trial name
- NIRVANA (NCT06112756)
- Testing
- Elinzanetant
- Where
- 40 sites in United States, Austria and 5 more
- Volunteers
- 110 people
- Sponsor
- Bayer
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
Researchers are looking for a better way to treat participants who have diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD). DME is a diabetes-related eye disorder.
- Trial name
- DEUTERON (NCT06591598)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 51 people
- Sponsor
- Bayer
Metastatic Castration-resistant Prostate Cancer
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing…
- Trial name
- REASSURE (NCT02141438)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 68 sites in United States, Argentina and 18 more
- Volunteers
- 1,472 people
- Sponsor
- Bayer
Lymphoma,Non-Hodgkin
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have…
- Trial name
- CHRONOS-3 (NCT02367040)
- Testing
- Copanlisib (Aliqopa, BAY80-6946), Rituximab
- Where
- 187 sites in United States, Argentina and 35 more
- Volunteers
- 458 people
- Sponsor
- Bayer
Retinopathy of Prematurity (ROP)
Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090
This is a follow-up study to evaluate the long term outcome of babies treated in the FIREFLEYE study.
- Trial name
- FIREFLEYE next (NCT04015180)
- Testing
- Eylea (Aflibercept, BAY86-5321), Laser photocoagulation
- Where
- 55 sites in Argentina, Belgium and 22 more
- Volunteers
- 100 people
- Sponsor
- Bayer
Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
This is an observational study in which data already collected from people with chronic heart failure is studied. Chronic HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body as well…
- Trial name
- ROVER Japan (NCT06697353)
- Testing
- vericiguat (BAY 1021189)
- Where
- Japan
- Volunteers
- 4,936 people
- Sponsor
- Bayer
Hypertension, Pulmonary
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these trials until lack of patient benefit as…
- Trial name
- RIALTO (NCT02759419)
- Testing
- Adempas (Riociguat, BAY63-2521)
- Where
- 9 sites in France, South Korea
- Volunteers
- 18 people
- Sponsor
- Bayer
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Researchers are looking for a better way to treat people who have chronic heart failure with reduced ejection fraction. Chronic heart failure with reduced ejection fraction (HFrEF) is a long-term condition that occurs when the…
- Trial name
- NCT06195930
- Testing
- Vericiguat (BAY1021189) 5 mg
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 106 people
- Sponsor
- Bayer
Bone Metastatic Castration-resistant Prostate Cancer
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
In this study researcher want to gain more information on how the study drug (radium-223) is distributed in the bone, particularly in the tumor free bone in participants with prostate cancer.
- Trial name
- NCT04521361
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 12 sites in Austria, France and 4 more
- Volunteers
- 46 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.